Merck and Ridgeback to Present Data Demonstrating That Treatment With Lagevrio (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo

Additional Exploratory Patient Subgroup and Virology Data from MOVe-OUT Presented at ECCMID Among Patients With Infectious Virus at Baseline, No Patients Who Received Lagevrio Had Infectious Virus at Days 3, 5 or 10 KENILWORTH, N.J.&...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials